Submission Details
| 510(k) Number | K100375 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 12, 2010 |
| Decision Date | April 06, 2011 |
| Days to Decision | 418 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
K100375 is an FDA 510(k) clearance for the DIMENSION VISTA LOCI CA 19-9 FLEX REAGENT CARTRIDGE, AND DIMENSION LOCI7 CALIBRATOR WITH MODEL(S) K6457, AND KC604, a System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer (Class II — Special Controls, product code NIG), submitted by Siemens Healthcare Diagnostics, Inc. (Newark, US). The FDA issued a Cleared decision on April 6, 2011, 418 days after receiving the submission on February 12, 2010. This device falls under the Immunology review panel. Regulated under 21 CFR 866.6010.
| 510(k) Number | K100375 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 12, 2010 |
| Decision Date | April 06, 2011 |
| Days to Decision | 418 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
| Product Code | NIG — System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.6010 |
| Definition | An In Vitro Diagnostic Test For The Quantitative Measurement Of The Ca 19-9 Tumor Associated Antigen In Human Serum Or Plasma. The Test Is Intended As An Aid In The Management Of Patients With Confirmed Pancreatic Cancer And Serial Monitoring Of Their Response To Therapy And Disease Progression. The Test Should Only Be Used In Patients With Serum And Plasma Ca 19-9 Values Above The Cut-off At The Time Of Diagnosis And In Conjunction With Other Clinical Methods. |